Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study
C Besses, JJ Kiladjian, M Griesshammer, L Gugliotta… - Leukemia Research, 2013 - Elsevier
EXELS is an ongoing phase IV non-interventional study; 3643 high-risk patients with
essential thrombocythemia (ET) were recruited across 13 European countries. We report …
essential thrombocythemia (ET) were recruited across 13 European countries. We report …
Management of pregnant women with myeloproliferative neoplasms
N Lavi, B Brenner, I Avivi - Thrombosis Research, 2013 - Elsevier
Myeloproliferative neoplasms (MPNs) are generally considered to be diseases of elderly
population; however, 20% of subjects diagnosed with ET are younger than 40 years …
population; however, 20% of subjects diagnosed with ET are younger than 40 years …
[HTML][HTML] Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged> 80 years: an interim analysis of the EXELS study
JJ Kiladjian, C Besses, M Griesshammer… - Clinical drug …, 2013 - Springer
Background The median age of patients diagnosed with essential thrombocythaemia (ET) is
65–70 years but the management of very elderly patients (aged> 80 years) with ET has not …
65–70 years but the management of very elderly patients (aged> 80 years) with ET has not …
羟基脲联合干扰素治疗原发性血小板增多症疗效观察
宋通微， 洪澄英 - 临床合理用药杂志, 2013 - cqvip.com
目的观察羟基脲联合干扰素治疗原发性血小板增多症(ET) 的临床疗效. 方法56
例原发性血小板增多症患者, 根据治疗方案随机分为羟基脲组18 例; 羟基脲联合干扰素组20 例; …
例原发性血小板增多症患者, 根据治疗方案随机分为羟基脲组18 例; 羟基脲联合干扰素组20 例; …
[PDF][PDF] Nordic guidelines on the diagnosis and treatment of patients with Myeloproliferative Neoplasms
CL Andersen, B Andreasson, H Hasselbalch… - The European …, 2013 - myeloid.dk
The Nordic study group on myeloproliferative neoplasms (NMPN) is a pan-Nordic
organization that has conducted Nordic clinical trials since 2001. NMPN decided in 2006 to …
organization that has conducted Nordic clinical trials since 2001. NMPN decided in 2006 to …
[图书][B] Clinical and epidemiological studies in myeloproliferative neoplasms
M Hultcrantz - 2013 - search.proquest.com
Myeloproliferative neoplasms (MPN), including polycythemia vera (PV), essential
thrombocythemia (ET), and primary myelofibrosis (PMF), are clonal hematopoietic disorders …
thrombocythemia (ET), and primary myelofibrosis (PMF), are clonal hematopoietic disorders …
[PDF][PDF] ESANSİYEL TROMBOSİTEMİ VE PRİMER MİYELOFİBROZİS OLGULARINDA ASXL1, IDH1, IDH2 GEN MUTASYONLARI VE JAK2V617F ALLEL YÜKÜ İLE …
İ YÖNAL, FD Sargın - nek.istanbul.edu.tr
ESANSİYEL TROMBOSİTEMİ VE PRİMER MİYELOFİBROZİS OLGULARINDA ASXL1, IDH1,
IDH2 GEN MUTASYONLARI VE JAK2V617F ALLEL YÜKÜ Page 1 TC İSTANBUL …
IDH2 GEN MUTASYONLARI VE JAK2V617F ALLEL YÜKÜ Page 1 TC İSTANBUL …
Novel composition for treatment of essential thrombocythemia
R Widmann, G Strieder - US Patent App. 13/637,014, 2013 - Google Patents
The present invention relates to a novel pharmaceutical composition free of gastric coating
comprising anagrelide hydrochloride in combination with a non-pH dependent polymer and …
comprising anagrelide hydrochloride in combination with a non-pH dependent polymer and …
Update on the treatment of Ph-negative myeloproliferative neoplasms
Myeloproliferative neoplasms (MPNs) that do not harbor the BCR–ABL rearrangement
include polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis …
include polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis …
[PDF][PDF] Interaktion der Thrombozyten und des von Willebrand Faktors in Patienten mit Essentieller Thrombozythämie und Polyzythämia vera
E Kapfhammer - 2013 - edoc.ub.uni-muenchen.de
Interaktion der Thrombozyten und des von Willebrand Faktors in Patienten mit Essentieller
Thrombozythämie und Polyzythämia ver Page 1 1 Abteilung für Transfusionsmedizin …
Thrombozythämie und Polyzythämia ver Page 1 1 Abteilung für Transfusionsmedizin …